CD85g (ILT7) Monoclonal Antibody (eBio17G10.2 (17G10.2)), PE, eBioscience™, Invitrogen™

Description

• Description: The eBio17G10.2 monoclonal antibody reacts with human immunoglobulin-like transcript 7 (ILT7), also known as CD85g
• ILT7 is part of the leukocyte immunoglobulin-like receptor (LIR) gene family and associates with Fc epsilon R1 gamma to form a functional complex which transduces ITAM-mediated signals that negatively modulates TLR-induced type I IFN production by human plasmacytoid dendritic cells
• ILT7 is expressed exclusively on plasmacytoid dendritic cells and is absent in monocyte derived DCs
• Treatment with IL-3 or CpG causes a decrease in expression
• Double staining of human PBMCs with eBio17G10.2 and anti-pDC marker BDCA2 yields virtually complete co-staining
• Cross linking of ILT7 with eBio17G10.2 antibody causes reduced transcription of IFN alpha1, IFN alpha2, IFN alpha4 and IFN beta
• Applications Reported: This eBio17G10.2 (17G10.2) antibody has been reported for use in flow cytometric analysis
• Applications Tested: This eBio17G10.2 (17G10.2) antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at 5 μL (0.125 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser
• Filtration: 0.2 μm post-manufacturing filtered
• ILT7 is a pDC-specific IgG-like transcript and is a member of the leukocyte immunoglobulin-like receptor gene family
• This receptor, in complex with FcER1a, transduces ITAM-mediated signals which negatively modulate type I IFN production by pDC
• ILT7 is thus a potential target to regulate Type 1 IFN production by pDC, which play a major role during viral infection, auto-immune diseases and anti-cancer immunity
• Additionally, ILT7, along with CD123 and BDCA-2, can be used to identify or classify subsets of pDCalong with TLR expression and TLR mediated immune responses.